Invivyd (NASDAQ:IVVD – Get Free Report) and Pharming Group (NASDAQ:PHAR – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, risk, profitability, analyst recommendations and dividends.
Analyst Ratings
This is a summary of current recommendations and price targets for Invivyd and Pharming Group, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Invivyd | 1 | 1 | 3 | 0 | 2.40 |
| Pharming Group | 0 | 2 | 3 | 0 | 2.60 |
Invivyd currently has a consensus target price of $10.00, suggesting a potential upside of 1,662.74%. Pharming Group has a consensus target price of $39.67, suggesting a potential upside of 206.31%. Given Invivyd’s higher probable upside, equities analysts clearly believe Invivyd is more favorable than Pharming Group.
Profitability
This table compares Invivyd and Pharming Group’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Invivyd | -183.90% | -59.73% | -48.97% |
| Pharming Group | 6.23% | 8.70% | 4.93% |
Insider & Institutional Ownership
70.4% of Invivyd shares are owned by institutional investors. Comparatively, 0.0% of Pharming Group shares are owned by institutional investors. 12.2% of Invivyd shares are owned by insiders. Comparatively, 2.1% of Pharming Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Valuation and Earnings
This table compares Invivyd and Pharming Group”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Invivyd | $53.43 million | 3.13 | -$52.49 million | ($0.33) | -1.72 |
| Pharming Group | $376.13 million | 2.44 | $2.85 million | $0.32 | 40.47 |
Pharming Group has higher revenue and earnings than Invivyd. Invivyd is trading at a lower price-to-earnings ratio than Pharming Group, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Invivyd has a beta of 1.2, suggesting that its share price is 20% more volatile than the S&P 500. Comparatively, Pharming Group has a beta of -0.05, suggesting that its share price is 105% less volatile than the S&P 500.
Summary
Pharming Group beats Invivyd on 7 of the 12 factors compared between the two stocks.
About Invivyd
Invivyd is a biotechnology company focused on developing antibody-based medicines to help prevent and treat infectious diseases, with an emphasis on COVID-19. Its work includes discovering and engineering monoclonal antibodies intended to retain activity against changing viral variants. The company’s lead product, pemivibart, is marketed in the United States as PEMGARDA. The U.S. Food and Drug Administration authorized it for emergency use as pre-exposure prevention of COVID-19 in certain people with moderate-to-severe immune compromise who may not have an adequate response to vaccination.
About Pharming Group
Pharming Group N.V. is a biotechnology company headquartered in Leiden, the Netherlands, that develops and commercializes medicines for rare and underserved diseases. Founded in 1988, the company has built its business around treatments for disorders involving the immune system. Its marketed products include Ruconest (conestat alfa), a recombinant human C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, and Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
